Skip to Content

Atogepant FDA Approval Status

Last updated by Judith Stewart, BPharm on Nov 19, 2019.

FDA Approved: No
Generic name: atogepant
Company: Allergan plc
Treatment for: Migraine Prevention

Atogepant is a novel, highly potent, orally-administered CGRP receptor antagonist in development for the prevention of migraine.

Development Timeline for atogepant

DateArticle
Mar 30, 2021U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine
Jul 29, 2020AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.